157369-85-2

Basic information

• Product Name: (R)-(-)-IBUPROFEN, (S)-(+)-LYSINATE
• Synonyms: (R)-(-)-IBUPROFEN, (S)-(+)-LYSINATE;(aR)-a-Methyl-4-(2-methylpropyl)benzeneacetic Acid L-Lysine;Ibuprofen Impurity 41
• CAS NO: 157369-85-2
• Molecular Formula: C19H32N2O4
• Molecular Weight: 352.47
• Product Categories: Chiral Reagents;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 157369-85-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 185-187°C
• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Methanol, Water
• CAS DataBase Reference: (R)-(-)-IBUPROFEN, (S)-(+)-LYSINATE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(-)-IBUPROFEN, (S)-(+)-LYSINATE(157369-85-2)
• EPA Substance Registry System: (R)-(-)-IBUPROFEN, (S)-(+)-LYSINATE(157369-85-2)

Safety Data

• Hazardous Substances Data: 157369-85-2(Hazardous Substances Data)

Usage

Chemical Properties

White Cyrstalline Solid

Uses

A nonsteroidal anti-inflammatory drug (NSAID). Optically active, selective cyclooxygenase inhibitor (IC50=14.9uM). Inhibits PGH synthase-1 and PGH synthase-2 with comparable potency

Upstream product

• 113403-10-4 (S)-(+)-ibuprofen (S)-lysinate 
• 56-87-1 L-lysine 
• 15687-27-1 ibuprofen 
• 51146-56-6 (S)-ibuprofen 
• 70-54-2 2,6-diaminocaproic acid 

Downstream Products

• 51146-56-6 (S)-ibuprofen 
• 15687-27-1 ibuprofen 
• 51146-57-7 (R)-ibuprofene 
• 113403-10-4 (R)-(-)-ibuprofen (S)-lysinate 

Relevant articles and documents

Preparation method of lysinoprofen

The invention belongs to the technical field of medicine preparation, and particularly relates to a preparation method of lysinoprofen. The preparation method comprises the following steps: concentrating lysine hydrochloride and then reacting lysine hydrochloride with ibuprofen, and decolorizing with activated carbon, and crystallizing with ethyl acetate to obtain the product. The method for preparing lysinoprofen is simple, does not need special equipment, and is simple and convenient to operate and good in process controllability; and the prepared finished product is good in quality and highin purity.

Pharmaceutical compositions containing the salts of S(+)-2-(4-isobutylphenyl)propionic acid with basic aminoacids

A pharmaceutical composition for oral use containing the salt of S(+)-2-(4-isobutylphenyl)propionic acid with a basic aminoacid selected between L-arginine and L-lysine is described.

Racemization of an enantomerically enriched α-aryl carboxylic acid

There is disclosed and claimed a process whereby S(+)-ibuprofen L-lysinate salt is produced by selective precipitation from a mixture containing enantiomers of ibuprofen and L-lysine. The quantity of L-lysine is not more than about a molar equivalent of the quantity of S(+)-ibuprofen in the ibuprofen enantiomeric mixture. The mother liquors after separating the above salt are enriched in R-ibuprofen which is racemized by a novel thermal racemization process and may then be recycled.